Table 1 Demographic and clinical characteristics
Study population (1776 patients; 12,094 visits) | ||
|---|---|---|
With MTC (v = 3077) | Without MTC (v = 9017) | |
Age, mean years (SD) [95% CI] | 63.1 (11.0) [62.7–63.5] | 65.6 (10.7) [65.4–65.9] |
Male sex, n (%) [95% CI] | 2784 (90.5) [89.4–91.5] | 8190 (90.8) [90.2–91.4] |
Caucasian race, n (%) [95% CI] | 2349 (76.3) [74.8–77.8] | 7135 (79.1) [78.3–80.0] |
RA duration, mean years (SD) [95% CI] | 14.0 (11.6) [13.9–14.7] | 15.7 (11.7) [15.5–16.0] |
RDCI score mean (SD) [95% CI] | 2.3 (1.5) [2.2–2.3] | 2.3 (1.5) [2.2–2.3] |
RF status, n (%) [95% CI] | ||
Positive | 2743 (89.1) [88.0–90.2] | 8005 (88.8) [88.1–89.4] |
Negative | 328 (10.7) [9.6–11.8] | 995 (11.0) [10.4–11.7] |
Missing | 6 (0.2) [0.1–0.4] | 17 (0.2) [0.1–0.3] |
ACPA status, n (%) [95% CI] | ||
Positive | 2572 (83.6) [82.2–84.9] | 7491 (83.1) [82.3–83.8] |
Negative | 497 (16.2) [14.9–17.5] | 1501 (16.6) [15.9–17.4] |
Missing | 8 (0.3) [0.1–0.5] | 25 (0.3) [0.2–0.4] |
DAM stability, n (%) [95% CI] | ||
Better or no change | 2146 (69.7) [68.1–71.4] | 6299 (69.9) [68.9–70.8] |
Worse | 931 (30.3) [28.6–31.9] | 2718 (30.1) [29.2–31.1] |
Recent dispensing episodesa, n (%) [95% CI] | ||
bDMARD | 348 (11.3) [10.2–12.5] | 1396 (15.5) [14.7–16.2] |
csDMARD | 646 (21.0) [19.6–22.5] | 2710 (30.1) [29.1–31.0] |
Prednisone | 308 (10.0) [9.0–11.1] | 731 (8.1) [7.6–8.7] |
Established dispensing episodesb, n (%) [95% CI] | ||
bDMARD | 1171 (38.1) [36.3–39.8] | 3808 (42.2) [41.2–43.3] |
csDMARD | 2609 (84.8) [83.5–86.0] | 8104 (89.9) [89.2–90.5] |
Prednisone | 1628 (52.9) [51.1–54.7] | 3580 (39.7) [38.7–40.7] |
Baseline MTC before index visit, n (%) [95% CI] | ||
8–30 days | 45 (1.5) [1.1–2.0] | 137 (1.5) [1.3–1.8] |
8–60 days | 161 (5.2) [4.5–6.1] | 539 (6.0) [5.5–6.5] |
8–90 days | 292 (9.5) [8.5–10.6] | 1134 (12.6) [11.9–13.3] |